Tiba Biotech LLC
Tiba Biotech is a preclinical stage biopharmaceutical company developing next-generation RNA vaccines and therapeutics based on a novel dendrimer nanoparticle delivery platform. Their mission is to accelerate science and improve human health beyond borders by creating safer, more effective vaccines and therapeutics with relaxed cold-chain requirements and superior safety profiles. They focus on rapid response to infectious diseases, oncology, gene editing, and other therapeutic applications, leveraging continuous innovation in RNA delivery technology and strategic partnerships with government agencies and research institutions.
Industries
Nr. of Employees
small (1-50)
Patents
Nanoparticle compositions containing sugar functionalized nucleic acid carriers
US-11859201-B2
View Details
Nanoparticle compositions containing sugar functionalized nucleic acid carriers
US-11859201-B2
View DetailsProducts
RNA nanoparticle delivery platform (dendrimer-based)
A dendrimer-derived biodegradable nanoparticle delivery platform for nucleic acid payloads intended for vaccines and therapeutics, designed to enable large payloads with reduced carrier-associated immunogenicity and relaxed cold-chain needs.
RNA nanoparticle delivery platform (dendrimer-based)
A dendrimer-derived biodegradable nanoparticle delivery platform for nucleic acid payloads intended for vaccines and therapeutics, designed to enable large payloads with reduced carrier-associated immunogenicity and relaxed cold-chain needs.
Services
Partnership-based preclinical research to benchmark nucleic acid delivery platforms and advance vaccine and therapeutic candidates.
Contract R&D to develop RNA vaccine or therapeutic candidates, including formulation, delivery optimization, and preclinical testing.
Support for small-scale manufacture and transfer of RNA vaccine candidates to regional manufacturing sites and pilot facilities.
Partnership-based preclinical research to benchmark nucleic acid delivery platforms and advance vaccine and therapeutic candidates.
Contract R&D to develop RNA vaccine or therapeutic candidates, including formulation, delivery optimization, and preclinical testing.
Support for small-scale manufacture and transfer of RNA vaccine candidates to regional manufacturing sites and pilot facilities.
Expertise Areas
- RNA delivery and nanoparticle engineering
- RNA vaccine R&D (self-amplifying and multi-antigen constructs)
- Therapeutic RNA development (siRNA/RNAi)
- Preclinical program design and animal immunology studies
Key Technologies
- Dendrimer-based nanoparticle delivery
- Biodegradable polymeric carriers
- Self-amplifying RNA constructs
- siRNA / RNAi therapeutics
News & Updates
Tiba secures a FASTx award from BARDA to develop an RNAi-based therapeutic for H1N1 influenza, extending their RNABL™ delivery platform beyond vaccines.
The government of NSW (Australia) invests in a project to fast-track an mRNA vaccine for border disease virus (BDV), successfully manufactured in NSW for the first time.
CEPI and Tiba evaluate next-generation RNA vaccine platform technology, including a candidate vaccine against Japanese Encephalitis Virus (JEV).
Tiba Biotech and CEPI are planning ahead for the next pandemic, advancing dendrimer-based nanoparticles demonstrating greater gene expression with lower immunogenicity.
M.I.T. and Whitehead Institute file initial provisional patent application for a novel class of dendrimer nanoparticles.
Research published on dendrimer-RNA nanoparticles generating protective immunity against Ebola, H1N1, and Toxoplasma gondii.
Tiba secures a FASTx award from BARDA to develop an RNAi-based therapeutic for H1N1 influenza, extending their RNABL™ delivery platform beyond vaccines.
The government of NSW (Australia) invests in a project to fast-track an mRNA vaccine for border disease virus (BDV), successfully manufactured in NSW for the first time.
CEPI and Tiba evaluate next-generation RNA vaccine platform technology, including a candidate vaccine against Japanese Encephalitis Virus (JEV).
Tiba Biotech and CEPI are planning ahead for the next pandemic, advancing dendrimer-based nanoparticles demonstrating greater gene expression with lower immunogenicity.
M.I.T. and Whitehead Institute file initial provisional patent application for a novel class of dendrimer nanoparticles.
Research published on dendrimer-RNA nanoparticles generating protective immunity against Ebola, H1N1, and Toxoplasma gondii.